Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CAMBRIDGE, MASS.--(BUSINESS WIRE)--AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) (AMYLYX OR THE COMPANY) TODAY REPORTED FINANCIAL AND BUSINESS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025. ENTERING THE FINAL MONTHS OF 2025, WE ARE FOCUSED ON EXECUTION AS WE HEAD TOWARD A TRANSFORMATIVE YEAR IN 2026, WITH TOPLINE DATA EXPECTED FROM THE PIVOTAL PHASE 3 LUCIDITY TRIAL, SAID JOSHUA COHEN AND JUSTIN KLEE, CO-CEOS OF AMYLYX. WE CONTINUE TO ADVANCE OUR LEAD ASSET AVEXITIDE, AN INVESTIGA.

AMYLYX PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. IF YOU CURRENTLY OWN AMYLYX STOCK AND ARE A LONG-TERM SHAREHOLDER, YOU MAY BE ABLE TO SEEK CORPORATE GOVERNANCE REFORMS, THE RETURN OF FUNDS BACK TO THE COMPANY, A COURT-APPROVED FINANCIAL INCENTIVE AWARD, OR OTHER RELIEF AND BENEFITS. PLEASE CLICK HERE TO LEARN MORE ABOUT.

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

NEW YORK , OCT. 22, 2025 /PRNEWSWIRE/ -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. ACCORDING TO A FEDERAL SECURITIES LAWSUIT, AMYLYX INSIDERS CAUSED THE COMPANY TO MISREPRESENT OR FAIL TO DISCLOSE THAT (I) RELYVRIO'S COMMERCIAL PROSPECTS WERE OVERSTATED; (II) PATIENTS WERE DISCONTINUING TREATMENT WITH RELYVRIO AFTER SIX MONTHS; (III) THE RATE AT WHICH NEW PATIENTS WERE STARTING TREATMENT WITH RELYVRIO WAS DECREASING; (IV) ACCORDINGLY, RELYVRIO'S PRESCRIPTION RATE WAS ALSO OVERSTATED; (V) INSIDERS ATTEMPTED TO HIDE THE FOREGOING NEGATIVE TRENDS FROM INVESTORS AND THE MARKET BY BLOCKING ANALYSTS FROM VIEWING RELYVRIO'S PRESCRIPTION DATA; AND (VI) AS A RESULT, THE COMPANY'S PUBLIC STATEMENTS WERE MATERIALLY FALSE AND MISLEADING AT ALL RELEVANT TIMES.

KUEHN LAW ENCOURAGES INVESTORS OF AMYLYX PHARMACEUTICALS, INC. TO CONTACT LAW FIRM

NEW YORK , OCT. 6, 2025 /PRNEWSWIRE/ -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. ACCORDING TO A FEDERAL SECURITIES LAWSUIT, AMYLYX INSIDERS CAUSED THE COMPANY TO MISREPRESENT OR FAIL TO DISCLOSE THAT (I) RELYVRIO'S COMMERCIAL PROSPECTS WERE OVERSTATED; (II) PATIENTS WERE DISCONTINUING TREATMENT WITH RELYVRIO AFTER SIX MONTHS; (III) THE RATE AT WHICH NEW PATIENTS WERE STARTING TREATMENT WITH RELYVRIO WAS DECREASING; (IV) ACCORDINGLY, RELYVRIO'S PRESCRIPTION RATE WAS ALSO OVERSTATED; (V) INSIDERS ATTEMPTED TO HIDE THE FOREGOING NEGATIVE TRENDS FROM INVESTORS AND THE MARKET BY BLOCKING ANALYSTS FROM VIEWING RELYVRIO'S PRESCRIPTION DATA; AND (VI) AS A RESULT, THE COMPANY'S PUBLIC STATEMENTS WERE MATERIALLY FALSE AND MISLEADING AT ALL RELEVANT TIMES.

CAMBRIDGE, MASS.--(BUSINESS WIRE)---- $AMLX--AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) (AMYLYX OR THE COMPANY) TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 17,500,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $10.00 PER SHARE. ALL OF THE SHARES OF COMMON STOCK ARE BEING OFFERED BY AMYLYX. IN ADDITION, AMYLYX HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 2,625,000 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE PER SHARE, LES.

AMYLYX PHARMACEUTICALS ANNOUNCES PRICING OF $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

CAMBRIDGE, MASS.--(BUSINESS WIRE)---- $AMLX--AMYLYX PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.

AMYLYX PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

CAMBRIDGE, MASS.--(BUSINESS WIRE)---- $AMLX--AMYLYX PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES.

AMYLYX PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

CAMBRIDGE, MASS.--(BUSINESS WIRE)---- $AMLX--AMYLYX PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS.

AMYLYX PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

CAMBRIDGE, MASS.--(BUSINESS WIRE)---- $AMLX--AMYLYX PHARMACEUTICALS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 7, 2025.

AMYLYX PHARMACEUTICALS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 7, 2025

CAMBRIDGE, MASS.--(BUSINESS WIRE)--AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) (AMYLYX OR THE COMPANY) TODAY ANNOUNCED THE PRESENTATION OF NEW EXPLORATORY ANALYSES FROM THE PHASE 2 PREVENT AND PHASE 2B CLINICAL TRIALS OF AVEXITIDE, AN INVESTIGATIONAL, FIRST-IN-CLASS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR ANTAGONIST FOR THE TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA (PBH) AT THE ENDOCRINE SOCIETY'S ANNUAL MEETING (ENDO 2025). IN THE PHASE 2B TRIAL, AVEXITIDE 90 MG ONCE DAILY, THE DOSE BEING.

AMYLYX PHARMACEUTICALS PRESENTS NEW EXPLORATORY ANALYSES FROM PHASE 2 AND PHASE 2B CLINICAL TRIALS OF AVEXITIDE IN POST-BARIATRIC HYPOGLYCEMIA AT ENDO 2025

CAMBRIDGE, MASS.--(BUSINESS WIRE)---- $AMLX--AMYLYX PHARMACEUTICALS TO HOST EVENT TO DISCUSS POST-BARIATRIC HYPOGLYCEMIA AND AVEXITIDE AT ENDO 2025.

Amylyx Pharmaceuticals, Inc.

AMLX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Amylyx Pharmaceuticals, Inc.

AMLX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AMLX